PETNET Solutions in the USA has executed a supply agreement with Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, to provide BMS747158 for PET imaging of cardiac perfusion as part of the Phase II and Phase III trials.
PETNET Solutions has previously supplied all of the clinical trial doses for the Lantheus Phase I study. BMS747158 is Lantheus’ novel fluorine 18-labeled Positron Emission Tomography (PET) tracer for myocardial perfusion imaging in subjects under rest and stress conditions.
PETNET Solutions is committed to advancing molecular imaging by support of clinical trials.
“Our agreement with Lantheus further emphasizes PETNET’s network as an attractive channel for novel PET agents,” said Tom Welch, chief executive officer of PETNET Solutions. “We are proud to be involved with BMS747158 as one of the many important R&D projects that we are actively engaged in. As the leading supplier of PET biomarkers, PETNET has the experience required to support the commercialization of new products, such as the Lantheus agent.”